Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer

Amit Bahl(At Bristol), Mark Churn(Guy's and St Thomas' NHS Foundation Trust), S. Spensley(Musgrove Park Hospital), Allan Hackshaw(Cancer Research UK), Duncan Wheatley(National Health Service), Mark Verrill(Newcastle upon Tyne Hospitals NHS Foundation Trust), Charles Comins(University Hospitals Bristol NHS Foundation Trust), Pavel Bezecny(Clinical Trial Investigators), Jessica Ball(University Hospitals Bristol NHS Foundation Trust), Peter W. Stephens(Stony Brook University), Jeremy Braybrooke(University Hospitals Bristol NHS Foundation Trust), Hannah Rose Kirk(University Hospitals Bristol NHS Foundation Trust), Rebecca Bowen, Sidharth Dubey(Derriford Hospital), William W. Wilson(Dakota State University), Alison Markham(University Hospitals Bristol NHS Foundation Trust), H. W. Evans(University Hospitals Bristol NHS Foundation Trust), Alicia Bravo(University Hospitals Bristol NHS Foundation Trust), Eve Watson, Simon Waters(Velindre Cancer Centre), Abigail Gee(University Hospitals Bristol NHS Foundation Trust), Vivek Mohan(University Hospitals Bristol NHS Foundation Trust), S.K. Pearson(University Hospitals Bristol NHS Foundation Trust), Emily Foulstone(University Hospitals Bristol NHS Foundation Trust), Janine Mansi(Guy's and St Thomas' NHS Foundation Trust), Mark Callaway(University Hospitals Bristol NHS Foundation Trust), Emily Renninson(University Hospitals Bristol NHS Foundation Trust), Pippa Riddle(Charing Cross Hospital), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust)
The Breast
September 24, 2022
Cited by 7


Related Papers